KD
Therapeutic Areas
Biofrontera Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ameluz® (BF-200 ALA) | Actinic Keratosis (AK) - Pharmacokinetics | N/A (Post-Approval Study) |
| Ameluz® | Actinic Keratosis | Approved |
| Xepi® | Impetigo | Approved |
Leadership Team at Biofrontera
PH
Prof. Hermann Luebbert, PhD
Chief Executive Officer & Chairman of the Board
FL
Fred Leffler
Chief Financial Officer
GJ
George Jones
Chief Commercial Officer
SW
Samantha Widdicombe
Senior Vice President of Sales & Marketing
JL
Jon Lyons, PhD, MBA
Vice President of Scientific & Medical Affairs
JJ
John J. Borer III, J.D.
Board of Directors
BJ
Beth J. Hoffman, Ph.D.
Board of Directors
DH
Dr. Heikki Lanckriet
Board of Directors